Answers are grounded in this paper and cite their sources.
OBJECTIVE By adsorbing uremic toxins, the oral adsorbent AST‐120 is anticipated to suppress progression of chronic kidney disease (CKD) and hence delay initiation of dialysis. We conducted a retrospective study to clarify the efficacy of AST‐120 in combination with the current basic treatments in CKD patients. METHODS Among 130 patients who initiated dialysis, 56 patients who had taken AST‐120 and 56 pair‐matched patients who had not taken AST‐120 were analyzed. Matching was conducted using propensity scores. Cumulative dialysis initiation rate and change in estimated glomerular filtration rate (_eGFR) were compared between the two groups. RESULTS At baseline, 42.9% of patients in the AST‐120 group and 35.7% in the control group had diabetic nephropathy (DN) as the primary renal disease, and the mean eGFR rates were 11.7 ± 7.9 and 11.0 ± 9.3 mL/min, respectively. The 24‐month cumulative dialysis initiation rates were 64.3% in the AST‐120 group and 94.5% in the control group (p _ 0.001). When _eGFR before and after baseline were compared, the speed of eGFR reduction was significantly retarded in the AST‐120 group (p _ 0.001), while no difference was observed in the control group. CONCLUSIONS AST‐120 may further improve the effectiveness of the current basic treatment in delaying CKD progression.
No takes yet. Share an insight, caveat, or question.
Maeda et al. (2011) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: